Full Press Release Details
Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results
Irvine, California, U.S.A., March 28,
2025 (Business Wire) - SBC Medical Group Holdings Incorporated (NASDAQ: SBC, "SBC Medical" or the "Company"),
a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial
results for - the three months ended December 31, 2024 and full year 2024.
Quarter 2024 Highlights
| Total revenues were $44 million, representing a 29% year-over-year decrease. | ||
| Gross profit was $34 million, representing a 22% year-over-year decrease. | ||
| Income from operations was $5 million, representing an 80% year-over-year decrease. | ||
| EBITDA 1 , which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease . EBITDA margin 1 was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. | ||
| Net income attributable to SBC Medical Group was $7 million , representing a 54% year-over-year decrease. | ||
| Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.06 for the three months ended December 31, 2024, representing a year-over-year decrease of 58%. |
Year 2024 Highlights
| Total revenues were $205 million, representing a 6% year-over-year increase. | ||
| Gross Profit was $156 million, representing a 14% year-over-year increase. | ||
| Income from operations was $70 million, representing a 1% year-over-year decrease. | ||
| EBITDA 1 , which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $89 million, representing an 8% year-over-year increase . EBITDA margin 1 was 43% for the year of 2024, compared to 43% for the year of 2023. | ||
| Net Income attributable to SBC Medical Group was $47 million , representing an 18% year-over-year increase. | ||
| Return on equity, which is defined as net income attributable to the Company divided by the average of shareholder's equity as of December 31, 2023, and December 31, 2024, was 28% representing a year-over-year decrease of 4 percentage points. | ||
| Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.48 for the twelve months ended December 31, 2024, representing a year-over-year increase of 14%. | ||
| Number of partner clinics was 251 as of December 31, 2024, representing an increase of 43 clinics from December 31, 2023. |
EBITDA and EBITDA Margin are non-GAAP financial measures. For more information on non-GAAP financial measure, please see the section
of "Use of Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP Results."
| Number of customers 2 in the last twelve months ended December 31, 2024, was 6.03 million, representing a 15% year-over-year increase. | ||
| Repeat rate for customers 3 who visited franchisee's clinics twice or more was 71 %. |
Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, "The year of 2024 was a momentous year for us, showcasing our
solid performance and sustained growth, culminating in our successful Nasdaq listing. We delivered strong 2024 results with top line
growing by 6% while bottom line surged 18% year over year. More encouragingly, supported by our extensive network of 251
clinics, we served 6.0 million loyal customers over the last twelve months, with a repeat rate exceeding 70%. As we continue to see increasing
global demand for aesthetic medical services, we remain committed to developing a strong franchising structure and network, and expanding
our business both domestically and internationally. Looking ahead, we remain dedicated to not only maintaining, but expanding, our competitive
edge while capturing the significant growth opportunities both at home and abroad. With these goals we aim to create long-term value
and drive sustainable growth for our shareholders."
Year 2024 Financial Results
revenues were $205 million, an increase of 6% year-over-year despite the negative impact of the discontinuation of the staffing business,
driven by the expansion of franchise clinics.
was $89 million, an increased 8% year-over-year due to one-time factors such as stock-based compensation expenses (USD 13.0 million).
However, excluding these one-time factors and foreign exchange impacts (USD 6.9 million), EBITDA increased 32% year-over-year.
income and expenses totaled USD 3 million, primarily driven by the gain on the sale of Cellpro Japan, partially offset by an
impairment loss on certain equity holdings. Consequently, net income attributable to SBC increased 18% year-over-year,
achieving both revenue and profit growth compared to the previous fiscal year.
2024, Japan's Ministry of Health, Labor and Welfare, the regulator of the medical industry, raised concerns regarding the expansion
of aesthetic medical business, and intensified competition, which led to the shake out of some hair removal clinics. Despite such a challenging
competitive environment, SBC Medical maintained its market leadership by driving market expansion through an appropriate pricing
strategy for franchise clinics. As a result, the number of customers reached 6 million, a 15% year-over-year increase,
while the number of unique customers4 grew 11% year-over-year to 1.9 million.
the overseas business, SBC Medical acquired Aesthetic Healthcare Holdings Pte. and its subsidiaries ("AHH") in
Singapore, securing a strategic footprint to function as the Company's business hub in Asia. Additionally, SBC Medical
launched the "SBC Wellness" employee benefit program and entered into a strategic partnership with B4A, a SaaS
company for aesthetic clinics in Japan, executing key initiatives to expand its business.
2 The number of customers
takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, but does not take account customers of AHH
3 The number of customers
takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, but does not take account customers of AHH
Clinics, but excluding free counseling
4 The number of unique
customers account for each individual customer only once, regardless of how many times they have used our clinics or franchise
FY2025, while the aesthetic dermatology market is expected to continue expanding, competition is also expected to intensify. To solidify
its dominant market position, SBC Medical will implement strategic price revision and other initiatives.
to support the long-term expansion of our franchise clinic network, the Company will revise its franchise fee structure starting
in April 2025. This revision aims to alleviate the initial financial burden on franchisees while introducing a tiered fee system aligned
with clinic scale and the consulting services provided by SBC Medical Group Co., Ltd.
the revised fee structure had been applied starting in April 2024, it is estimated that total revenues for fiscal year 2024 would have
decreased by approximately 10%. However, the Company expects the impact on total revenues and income from operations for fiscal year
2025 to be offset by the absence of one-time losses that were recorded in fiscal year 2024, which were impairment loss on intangible
assets and stock-based compensation. Nevertheless, the ultimate financial impact remains uncertain and will depend on a number of factors,
many of which are beyond the Company's control.
Company will hold a conference call on Friday, March 28, 2025, at 8:00 am Eastern Time (or Friday, March 28, 2025, at 9:00 pm Japan Time)
to discuss the financial results and take questions live.
register in advance of the conference using the link provided below. It will automatically direct you to the registration page of "SBC
2024 Full Year Financial Results Briefing". Please follow the steps to enter your registration details, then click "Submit".
Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call,
this site provides access to information about the speakers as well as past investor relations materials.
is accessible online at https://edge.media-server.com/mmc/p/demkfxps/.
10 minutes before the conference call begins, you will be able to view the full-year earnings presentation materials on the site. The
materials will also be available for download.
replay of the conference call will be accessible until March 28, 2026.
a live and archived webcast of this conference call will be available at https://ir.sbc-holdings.com/ .
Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment
centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited
to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and
training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals,
construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic
products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies,
trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise
clinic's customer rewards program (customer loyalty point program), and payment tools for the franchise clinics.
more information, visit https://sbc-holdings.com/
of Non-GAAP Financial Measures
Company uses non-GAAP measures, such as EBITDA, in evaluating its operating results and for financial and operational decision-making
purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes
that the non-GAAP financial measures provide useful information about the Company's results of operations, enhance the overall
understanding of the Company's past performance and future prospects and allow for greater visibility with respect to key metrics
used by the Company's management in its financial and operational decision-making.
non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial
measures have limitations as analytical tools, and when assessing the Company's operating performance, cash flows or liquidity,
investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other
consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.
Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures,
all of which should be considered when evaluating the Company's performance.
more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP
press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions,
but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently
uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with
respect to, among other things, the Company's financial performance; growth in revenue and earnings; business prospects and opportunities;
and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates," "believes,"
"plans," "projected," "predicts," "potential," or "hopes" or the negative
of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current
only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are
difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees
of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement
is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge